Who can use Sinopharm’s vaccine against covid-19, how effective it is and who is not recommended to use it, these are just some of the questions answered by the WHO in this regard.
Mexico City (apro). -The World Health Organization (WHO) Immunization Strategy Advisory Panel has issued a series of interim recommendations on the use of the inactivated covid-19 vaccine BIBP developed by Sinopharm/China National Pharmaceutical Group.
This is what you need to know.
Although the supply of the covid-19 vaccine is limited, health care workers are at a high risk of exposure, and the elderly should be given priority for vaccination.
It is not recommended for people under the age of 18 to use the vaccine because other studies in this age group have not been completed.
Countries can refer to the WHO priority development roadmap and the WHO values framework to determine the priority of the target population.
The data available for pregnant women using the COVID-19 BIBP vaccine is insufficient to assess the efficacy of the vaccine or the risks associated with the vaccine during pregnancy.
However, this vaccine is an inactivated vaccine with adjuvants and is usually used in many vaccines with a good safety record, including in pregnant women. Therefore, the efficacy of the covid-19 BIBP vaccine in pregnant women is expected to be comparable to that observed in non-pregnant women of similar age.
At the same time, WHO recommends the use of covid-19 BIBP vaccine in pregnant women when the benefits of vaccination outweigh the potential risks.
In order to assist pregnant women with this assessment, they should be provided with information about the risks of covid-19 during pregnancy; the possible benefits of vaccination in the context of local epidemiology; and the limitations of current safety data for pregnant women.
WHO does not recommend a pregnancy test before vaccination. The WHO does not recommend delaying pregnancy or considering termination of pregnancy due to vaccination.
The vaccine can be provided to people who have been infected with COVID-19 in the past. Within six months of the initial natural infection, available data show that symptomatic reinfections are rare. In view of the limited supply of vaccines, those infected with SARS-CoV-2 confirmed by PCR in the past six months can choose to postpone vaccination until the end of this period. In environments where mutations related to signs of immune escape occur, it is recommended to immunize as soon as possible after infection.
The vaccine’s efficacy in breastfeeding women is expected to be similar to that of other adults. The World Health Organization recommends the use of the covid-19 BIBP vaccine in breastfeeding women and other adults. WHO does not recommend stopping breastfeeding after vaccination.
People with human immunodeficiency virus (HIV) have an increased risk of severe COVID-19 disease. People living with HIV were not included in the trial, but because the vaccine cannot replicate, it is possible to vaccinate HIV-infected people in the recommended vaccination population. Whenever possible, information and advice should be provided to support individual assessments of benefits and risks.
People with a history of allergy to any component of the vaccine should not take the vaccine.
Anyone whose body temperature is higher than 38.5ºC should postpone vaccination until the fever ceases.
The expert group (SAGE) recommends the use of BIBP vaccine in the form of 2 intramuscular injections (0.5 ml). WHO recommends that there should be an interval of 3 to 4 weeks between the first dose and the second dose. If the second dose is used less than 3 weeks after the first dose, there is no need to repeat the dose. If the second dose is delayed for more than 4 weeks, it should be administered as soon as possible. It is recommended that all vaccinated people receive two doses.